Last reviewed · How we verify
SGN-CD19A
At a glance
| Generic name | SGN-CD19A |
|---|---|
| Sponsor | Seagen Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma (PHASE2)
- Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma (PHASE2)
- A Safety Study of SGN-CD19A for B-Cell Lymphoma (PHASE1)
- A Safety Study of SGN-CD19A for Leukemia and Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGN-CD19A CI brief — competitive landscape report
- SGN-CD19A updates RSS · CI watch RSS
- Seagen Inc. portfolio CI